(Q82448827)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22071976%20AND%20SRC:MED&resulttype=core&format=json

16 January 2020

title

Gene expression profiles in peripheral blood as a biomarker in cancer patients receiving peptide vaccination (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22071976%20AND%20SRC:MED&resulttype=core&format=json

16 January 2020

1 reference

Nobukazu Komatsu

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22071976%20AND%20SRC:MED&resulttype=core&format=json

16 January 2020

Satoko Matsueda

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22071976%20AND%20SRC:MED&resulttype=core&format=json

16 January 2020

Kousuke Tashiro

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22071976%20AND%20SRC:MED&resulttype=core&format=json

16 January 2020

Tetsuya Ioji

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22071976%20AND%20SRC:MED&resulttype=core&format=json

16 January 2020

Shigeki Shichijo

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22071976%20AND%20SRC:MED&resulttype=core&format=json

16 January 2020

Masanori Noguchi

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22071976%20AND%20SRC:MED&resulttype=core&format=json

16 January 2020

Akira Yamada

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22071976%20AND%20SRC:MED&resulttype=core&format=json

16 January 2020

Atsushi Doi

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22071976%20AND%20SRC:MED&resulttype=core&format=json

16 January 2020

Shigetaka Suekane

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22071976%20AND%20SRC:MED&resulttype=core&format=json

16 January 2020

Fukuko Moriya

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22071976%20AND%20SRC:MED&resulttype=core&format=json

16 January 2020

Kei Matsuoka

11

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22071976%20AND%20SRC:MED&resulttype=core&format=json

16 January 2020

Satoru Kuhara

12

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22071976%20AND%20SRC:MED&resulttype=core&format=json

16 January 2020

Kyogo Itoh

13

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22071976%20AND%20SRC:MED&resulttype=core&format=json

16 January 2020

Tetsuro Sasada

14

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22071976%20AND%20SRC:MED&resulttype=core&format=json

16 January 2020

publication date

9 November 2011

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22071976%20AND%20SRC:MED&resulttype=core&format=json

16 January 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22071976%20AND%20SRC:MED&resulttype=core&format=json

16 January 2020

volume

118

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22071976%20AND%20SRC:MED&resulttype=core&format=json

16 January 2020

issue

12

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22071976%20AND%20SRC:MED&resulttype=core&format=json

16 January 2020

page(s)

3208-3221

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22071976%20AND%20SRC:MED&resulttype=core&format=json

16 January 2020

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26636

7 January 2021

gp100 peptide vaccine and interleukin-2 in patients with advanced melanoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26636

7 January 2021

Sipuleucel-T immunotherapy for castration-resistant prostate cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26636

7 January 2021

Vaccination against HPV-16 oncoproteins for vulvar intraepithelial neoplasia

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26636

7 January 2021

Overcoming the hurdles of randomised clinical trials of therapeutic cancer vaccines

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26636

7 January 2021

Recommendations from the iSBTc-SITC/FDA/NCI Workshop on Immunotherapy Biomarkers

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26636

7 January 2021

Improved Endpoints for Cancer Immunotherapy Trials

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26636

7 January 2021

Immunologic biomarkers as correlates of clinical response to cancer immunotherapy

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26636

7 January 2021

Polymorphisms in inflammation genes and bladder cancer: from initiation to recurrence, progression, and survival

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26636

7 January 2021

Influence of cytotoxic T lymphocyte-associated antigen 4 (CTLA4) common polymorphisms on outcome in treatment of melanoma patients with CTLA-4 blockade

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26636

7 January 2021

Multiplex analysis of serum cytokines in melanoma patients treated with interferon-alpha2b.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26636

7 January 2021

Serum vascular endothelial growth factor and fibronectin predict clinical response to high-dose interleukin-2 therapy

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26636

7 January 2021

A gene-expression signature as a predictor of survival in breast cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26636

7 January 2021

Gene-expression profiling in vaccine therapy and immunotherapy for cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26636

7 January 2021

Immune profile and mitotic index of metastatic melanoma lesions enhance clinical staging in predicting patient survival

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26636

7 January 2021

Gene-expression profiling for rejection surveillance after cardiac transplantation

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26636

7 January 2021

Assessing the human immune system through blood transcriptomics

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26636

7 January 2021

Identification of a B cell signature associated with renal transplant tolerance in humans.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26636

7 January 2021

Personalized peptide vaccines: a new therapeutic modality for cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26636

7 January 2021

A randomized phase II trial of personalized peptide vaccine plus low dose estramustine phosphate (EMP) versus standard dose EMP in patients with castration resistant prostate cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26636

7 January 2021

Phase I trial of a personalized peptide vaccine for patients positive for human leukocyte antigen--A24 with recurrent or progressive glioblastoma multiforme.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26636

7 January 2021

Assessment of immunological biomarkers in patients with advanced cancer treated by personalized peptide vaccination

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26636

7 January 2021

Integrated data from 2 randomized, double-blind, placebo-controlled, phase 3 trials of active cellular immunotherapy with sipuleucel-T in advanced prostate cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26636

7 January 2021

Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26636

7 January 2021

Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26636

7 January 2021

Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer: updated survival in the TAX 327 study

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26636

7 January 2021

The MicroArray Quality Control (MAQC) project shows inter- and intraplatform reproducibility of gene expression measurements

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26636

7 January 2021

Arginine regulation by myeloid derived suppressor cells and tolerance in cancer: mechanisms and therapeutic perspectives

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26636

7 January 2021

Angiogenesis and immunity: a bidirectional link potentially relevant for the monitoring of antiangiogenic therapy and the development of novel therapeutic combination with immunotherapy

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26636

7 January 2021

Why don't we get more cancer? A proposed role of the microenvironment in restraining cancer progression

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26636

7 January 2021

Immune regulation of cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26636

7 January 2021

The wolf in sheep's clothing: the role of interleukin-6 in immunity, inflammation and cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26636

7 January 2021

Analysis of complex biomarkers for human immune-mediated disorders based on cytokine responsiveness of peripheral blood cells

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26636

7 January 2021

Polymorphisms in leucine-rich repeat genes are associated with autism spectrum disorder susceptibility in populations of European ancestry

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26636

7 January 2021

Frequent silencing of protocadherin 17, a candidate tumour suppressor for esophageal squamous cell carcinoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26636

7 January 2021

Decoding the histone H4 lysine 20 methylation mark

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26636

7 January 2021

Review: Mammalian peptidoglycan recognition proteins (PGRPs) in innate immunity

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26636

7 January 2021

Arginase I-producing myeloid-derived suppressor cells in renal cell carcinoma are a subpopulation of activated granulocytes

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26636

7 January 2021

Myeloid-derived suppressor cells in the peripheral blood of cancer patients contain a subset of immature neutrophils with impaired migratory properties

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26636

7 January 2021

Myeloid-derived suppressor cells as regulators of the immune system

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26636

7 January 2021

Myeloid-derived suppressor cells: linking inflammation and cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26636

7 January 2021

Myeloid-derived suppressor cell heterogeneity and subset definition.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26636

7 January 2021

Tumor-associated neutrophils: new targets for cancer therapy

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26636

7 January 2021

Polarization of tumor-associated neutrophil phenotype by TGF-beta: "N1" versus "N2" TAN

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26636

7 January 2021

Neutrophil elastase-mediated degradation of IRS-1 accelerates lung tumor growth

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26636

7 January 2021

Neutrophils responsive to endogenous IFN-beta regulate tumor angiogenesis and growth in a mouse tumor model

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26636

7 January 2021

Presence of intratumoral neutrophils is an independent prognostic factor in localized renal cell carcinoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26636

7 January 2021

Gemcitabine selectively eliminates splenic Gr-1+/CD11b+ myeloid suppressor cells in tumor-bearing animals and enhances antitumor immune activity

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26636

7 January 2021

5-Fluorouracil selectively kills tumor-associated myeloid-derived suppressor cells resulting in enhanced T cell-dependent antitumor immunity

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26636

7 January 2021

Sunitinib mediates reversal of myeloid-derived suppressor cell accumulation in renal cell carcinoma patients

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26636

7 January 2021

The soluble leukocyte-associated Ig-like receptor (LAIR)-2 antagonizes the collagen/LAIR-1 inhibitory immune interaction

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26636

7 January 2021

Prognostic significance of interleukin 6 serum levels in patients with ovarian cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26636

7 January 2021

Elevated serum interleukin-6 levels in patients with pancreatic cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26636

7 January 2021

Interleukin-6 predicts recurrence and survival among head and neck cancer patients

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26636

7 January 2021

Tumor-induced tolerance and immune suppression depend on the C/EBPbeta transcription factor.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26636

7 January 2021

Characterization of cytokine-induced myeloid-derived suppressor cells from normal human peripheral blood mononuclear cells

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26636

7 January 2021

Identifiers

DOI

10.1002/CNCR.26636

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22071976%20AND%20SRC:MED&resulttype=core&format=json

16 January 2020

1 reference